Genomic and proteomic determinants of lower extremity revascularization failure: Rationale and study design

Study overview. LE PAOD, lower extremity peripheral arterial occlusive disease; CLI, critical limb ischemia; ABI, ankle-brachial index; SF-36, Short Form 36.

Study timeline. ABI, Ankle-brachial index; SF-36, Short Form 36.

Timing of phlebotomy for genomic and proteomic analysis. See Fig 2 for correlation with clinical outcome assessment. WBC, White blood cells; MO RNA, monocyte ribonucleic acid.

A, Representative heat map display of microarray data using time series (B) and supervised analytic approaches. MODS, multiorgan dysfunction syndrome. (Used by permission, Feezor RJ, Baker HV, Xiao W, et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol 2004;172:7103-9.)⁶²

Representative proteomic heat map. MODS, Multiorgan dysfunction syndrome; IL, interleukin; MCP-1, monocyte chemotactic protein-1; IP-10, interferon-γ inducible protein-10; MIG, monokine induced by IFNγ; sICAM, soluble intercellular adhesion molecule-1; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand treatment; IFNg, interferon-γ; TGFb, transforming growth factor-β; GM-CSF, granulocyte-macrophage colony-stimulating factor; GCSF, granulocyte colony-stimulating factor; TNFα, tumor necrosis factor-α; MCP-3, monocyte chemotactic protein-3; TNFβ, tumor necrosis factor-β. (Used by permission, Feezor RJ, Baker HV, Xiao W, et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol 2004;172:7103-9.)⁶²

Representative display of inflammatory pathway analysis (Ingenuity Pathway Analysis, Ingenuity Systems, www.ingenuity.com).